Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform

- This research collaboration marks Antengene's entry into the field of cellular medicines.

SHANGHAI and HONG KONGJuly 19, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a pre-clinical research collaboration with Celularity Inc. (NASDAQ: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies. Antengene and Celularity will evaluate the potential therapeutic synergy combining Antengene's bispecific antibody with Celularity's cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy platform.

Dr. Jay Mei, Antengene's Founder, Chairman and CEO said, "Evaluating new technologies that may have the potential to improve cancer care, either as monotherapy or in synergistic combination with programs, is essential to Antengene's mission. After a careful and comprehensive evaluation, Antengene is very pleased to initiate its first research collaboration in the important field of cellular medicine with Celularity."

Dr. Mei continued, "Celularity's proprietary, novel, allogenic, cryopreserved, off-the-shelf placental-derived cellular medicine platform is very exciting to Antengene. We look forward to collaborating with the company to explore the potential synergies from the combination of Antengene's bispecific antibody, and Celularity's investigational NK cell therapy programs, together or in combination with other agents such as antibodies that target tumor associated antigens (TAA). We are hopeful that this collaboration will yield potential new combination therapies that will improve the treatment of patients with hematological and solid tumor cancers."

Dr. Bo Shan, Antengene's Chief Scientific Officer said, "We are pleased to partner with Celularity's NK cell platform. The rationale for our collaboration is based on two hypotheses, formed from a foundation of preclinical and clinical research. First, that our bispecific antibody, potentially activating NK cells upon immune checkpoint inhibitors (ICI) crosslinking in the tumor microenvironment (TME), can synergize with TAA antibodies to enhance the anti-tumor response. Second, that our bispecific antibody may enhance the proliferation of NK cells and increase their persistence in TME."

Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity, added, "We are excited to enter into this research collaboration with Antengene to forge new therapeutic strategies for both solid tumors and hematological malignancies using our placental-derived cell therapy platform. There is an immense potential for combining two novel approaches to enhance tumor targeting while also enhancing allogeneic NK cell activation and activity within the tumor microenvironment. This strategy may identify novel therapeutic options targeting a wide range of cancers."

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

Since 2017, Antengene has a built broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO^® (selinexor) already approved in mainland China, South Korea, Singapore and Australia.

About Celularity

Celularity Inc., headquartered in Florham Park, N.J., USA, is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: [email protected]  
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: [email protected] 
Mobile: +86 13062747000

SOURCE Antengene Corporation Limited